Physician profile
Rina Basin
NPI 1881097152
$3,596.91
in general payments reported to CMS, 2019-2025
21 companies · $840 in 2025
The $840 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $648 · 2023: $355 · 2024: $760 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $554.76 | 2021-2025 | |
| Lilly USA, LLC | $513.04 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $309.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $299.74 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $265.64 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $250.96 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $209.41 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $209.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.98 | 2023-2025 | Jardiance |
| Abbott Laboratories | $149.26 | 2025 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $136.66 | 2025 | Amvuttra |
| Heartflow, INC. | $116.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $108.49 | 2021-2022 | |
| Pfizer INC. | $85.53 | 2022-2024 | |
| Philips North America LLC | $67.77 | 2024-2025 | Mcot, (Ck4) Mcot |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.54 | 2024 | Korlym |
| Amarin Pharma, INC. | $35.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.42 | 2021 | |
| Alfasigma USA, INC. | $20.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Basin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.